Bayer AG es una compañía de ciencias de la vida. Los segmentos de la compañía son productos farmacéuticos, salud del consumidor, ciencias de la cosecha, salud animal y Covestro.
El segmento de productos farmacéuticos se dedica al desarrollo de productos farmacéuticos recetados; anticonceptivos y productos médicos, como sistemas de inyección y agentes de contraste para procedimientos de diagnóstico.
El segmento de Salud del Consumidor se dedica al desarrollo de medicamentos de venta libre, productos dermatológicos y suplementos nutricionales.
New data for larotrectinib show overall response rates of 94% in children and 76% in adults with TRK fusion cancer; clinical benefit demonstrated in patients with primary central nervous system tumors and brain metastasesIn children with TRK fusion cancer (n=34), the overall response rate (ORR) was 94% and durable, with median duration of response (DOR) […]
Beiersdorf to acquire iconic Coppertone™ brand from BayerSignificant expansion of portfolio will advance Beiersdorf's leading position as sun care expert / Beiersdorf delivers first major acquisition under its new C.A.R.E.+ strategy / Divestiture enables Bayer to focus on core OTC businessmehr ...
Bayer to present new data at ASCO 2019 highlighting commitment to evolve cancer treatment paradigmData from Bayer's growing oncology portfolio include new analyses on the company's precision oncology treatment larotrectinib, with two oral presentations in patients with solid tumors that harbor an NTRK gene fusion: one on expanded data in pediatric patients and the other […]
Study reaffirms safety and efficacy profile of Xarelto™ for the prevention of stroke in patients with atrial fibrillationFirst results from RELOADED, an observational study in the EU, indicate that non-vitamin-K oral anticoagulants (NOACs) like Xarelto provide a benefit in renal preservation over time when compared to the vitamin-K antagonist (VKA) phenprocoumon / The data from […]
"We made great progress - both operationally and strategically"Bayer now the leader in agriculture / Lawsuits and first verdicts concerning glyphosate weigh on company / Sales and earnings increased in 2018 / Proposed dividend of 2.80 euros marks record payout by Bayer / Successful start to fiscal 2019 - outlook confirmedmehr ...
Bayer: strong operational start to the yearGroup sales increase 4.1 percent (Fx & portfolio adj.) to 13.015 billion euros / EBITDA before special items advances by 44.6 percent to 4.188 billion euros / Crop Science posts substantial sales and earnings gains following the acquisition / Pharmaceuticals shows encouraging sales and earnings growth / Consumer Health […]